Hospitalizations and Emergency Department Visits Before and After Omalizumab Treatment in Patients With Asthma and Food Allergies

Omalizumab is an anti-IgE antibody indicated for the treatment of moderate-to-severe persistent asthma. Food allergies may co-occur in up to 15% of patients with asthma, and children with both food allergy and asthma are at increased risk for life-threatening reactions. We compared all-cause and food allergy-related hospitalizations and emergency department (ED) visits before and after omalizumab treatment in patients with asthma and documented food allergies.

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: J. Andrew Bird, Julie Wang, Arpamas Seetasith, Vincent Garmo, Stella Ko, Inyoung Lee, Elizabeth Wang, Xiaohui Zhao, Aimee Near, Sachin Gupta, David Fleischer Source Type: research